Lord, Abbett & Co. LLC Immatics N.V. Transaction History

Lord, Abbett & Co. LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$7.36 - $10.89 $1.71 Million - $2.53 Million	-232,489 Reduced 45.25%	281,284 $2.96 Million
Q3 2023 Nov 13, 2023	BUY	$11.01 - $12.62 $297,996 - $341,572	27,066 Added 5.56%	513,773 $5.95 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $2.88 Million - $6.19 Million	486,707 New	486,707 $5.62 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.